Welcome to our dedicated page for Perspective Therapeutics SEC filings (Ticker: CATX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Perspective Therapeutics filings document a clinical-stage radiopharmaceutical oncology business built around Lead-212 targeted therapy, imaging diagnostics, and regional manufacturing capabilities. Form 8-K reports include clinical-program exhibits, corporate presentations, preliminary financial information, and annual results for its VMT-α-NET, VMT01, and PSV359 programs.
The company’s SEC record also covers capital-structure matters, including common stock and pre-funded warrant offerings under a shelf registration statement, as well as material agreements, proxy disclosures on board matters, executive compensation, equity awards, shareholder voting items, governance, and other public-company reporting obligations.
Perspective Therapeutics, Inc. (CATX) reported that it updated its corporate presentation, which has been furnished as an exhibit. The presentation outlines a strategy focused on next‑generation radiopharmaceutical therapy in targeted oncology built around lead‑212 (²¹²Pb) payloads.
The company highlights three independent clinical‑stage programs targeting distinct receptors or antigens: VMT-α-NET for SSTR2+ neuroendocrine tumors, VMT01 for melanoma via MC1R, and PSV359 for FAP-ɑ–expressing solid tumors, along with a CCK2R program. The materials describe an estimated $45 billion+ combined solid tumor addressable market for programs VMT-α-NET, VMT01, PSV359, and PSV594, ongoing Phase 1/2a trials, clinical data expected in 2026 including ASCO 2026 analyses, and an integrated platform covering isotope production, regional manufacturing, and intellectual property across the radiopharmaceutical value chain.
Perspective Therapeutics, Inc. (CATX) reported that Lantheus Alpha Therapy, LLC, a ten percent owner, sold shares of its common stock in open-market transactions on September 3 and September 4, 2026. The sales totaled 247,932 shares of common stock at weighted average prices around $3.11–$3.15 per share.
The shares are directly held by Lantheus Alpha Therapy, LLC, which is an indirect wholly owned subsidiary of Lantheus Holdings, Inc. Under SEC rules, Lantheus Holdings, Inc. may be deemed to have indirect beneficial ownership of these shares through Lantheus Alpha Therapy, LLC.
Perspective Therapeutics, Inc. (CATX) reported that significant stockholder Lantheus Alpha Therapy, LLC sold 42,129 shares of CATX common stock on September 2, 2026 in an open-market or private transaction at a weighted average price of $3.1147 per share, with individual trade prices ranging from $3.025 to $3.235. After this sale, Lantheus Alpha Therapy, LLC directly holds 11,521,296 CATX shares, and Lantheus Holdings, Inc., as its indirect parent, may be deemed to have indirect beneficial ownership of those shares under SEC rules.
Perspective Therapeutics, Inc. (CATX) disclosed that Lantheus Alpha Therapy, LLC, a ten percent owner and subsidiary of Lantheus Holdings, Inc., reported selling a total of 113,914 shares of CATX common stock in open-market or private transactions on August 31 and September 1, 2026. The August 31 sale covered 78,145 shares at a weighted average price of $3.143 per share, with individual trades between $3.095 and $3.165. The September 1 sale covered 35,769 shares at a weighted average price of $3.1193, with trades between $3.08 and $3.165. The share amounts reflect Perspective Therapeutics’ 1-for-10 reverse stock split effective June 14, 2024, and the filing notes that Lantheus Holdings may be deemed to have indirect beneficial ownership of the shares held directly by Lantheus Alpha Therapy.
Perspective Therapeutics, Inc. (CATX) discloses in this Schedule 13D/A (Amendment No. 2) that Lantheus Holdings, Inc., Lantheus Medical Imaging, Inc., and Lantheus Alpha Therapy, LLC collectively report beneficial ownership of 11,440,513 shares of CATX common stock, representing 10.0% of the class, based on 114,151,663 shares outstanding as of August 5, 2026. All shares are directly held by Lantheus Alpha, with all three Lantheus entities deemed to share voting and dispositive power.
The amendment is filed to reflect dilution of the reporting group’s beneficial ownership and to report dispositions of CATX shares on August 31, 2026, September 1, 2026, September 2, 2026 and September 3, 2026 at average prices just above $3.10 per share. It also notes a 1-for-10 reverse stock split of CATX common stock effective June 14, 2024 and confirms that the reported share figures are split-adjusted.
Perspective Therapeutics, Inc. (CATX) had a significant shareholder, Lantheus Holdings, Inc., report the sale of 35,769 shares of common stock on September 1, 2026 in a sale transaction. The weighted average sale price was $3.1193 per share, with individual trades between $3.08 and $3.165 per share.
After this transaction, an affiliated entity, Lantheus Alpha Therapy, LLC, directly held 11,563,425 shares of CATX common stock, and Lantheus Holdings may be deemed to have indirect beneficial ownership of those shares. No Rule 10b5-1 trading plan is reported for this sale.
Perspective Therapeutics, Inc. (CATX) had a significant shareholder, Lantheus Holdings, Inc., report that its wholly owned subsidiary Lantheus Alpha Therapy, LLC sold 78,145 shares of CATX common stock on August 31, 2026, at a weighted average price of $3.143 per share. After this open-market sale, the entity reported holding 11,599,194 CATX shares, adjusted to reflect a prior 1-for-10 reverse stock split effective June 14, 2024. No Rule 10b5-1 trading plan is reported for this transaction.
Perspective Therapeutics, Inc. is the subject of an amended ownership report by entities affiliated with Millennium Management. Integrated Core Strategies (US) LLC reports beneficial ownership of 5,888,184 shares of common stock, representing 5.2% of the class. Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander each report beneficial ownership of 6,316,545 shares, or 5.5% of the outstanding common stock.
All reporting persons list 0 shares with sole voting or dispositive power and instead report shared voting and shared dispositive power over their respective share amounts. The securities are held by entities subject to voting control and investment discretion by Millennium Management LLC and/or other investment managers controlled by Millennium Group Management LLC and Mr. Englander, and the group states that this should not be construed as an admission of beneficial ownership of the underlying securities.
Perspective Therapeutics, Inc. is a clinical-stage radiopharmaceutical company advancing multiple Lead-212–based cancer programs while significantly building its manufacturing and financial base. As of June 30, 2026, it held $48.5 million in cash and cash equivalents and $188.4 million in short‑term available‑for‑sale securities, for total cash, cash equivalents and short‑term investments of $236.9 million. Management believes this will fund current planned operations into late 2027.
For the six months ended June 30, 2026, grant revenue was $0.2 million and the net loss widened to $53.0 million from $39.7 million a year earlier, driven primarily by higher research and development expense of $42.9 million and continued build‑out of capabilities. The company completed a large underwritten equity financing and pre‑funded warrant issuance in February 2026, raising gross proceeds of approximately $175.0 million, and ended the period with $323.9 million of stockholders’ equity and an accumulated deficit of $387.8 million.
Perspective is progressing three core clinical programs (VMT‑α‑NET, VMT01 and PSV359), expanding a distributed manufacturing network including a Somerset, New Jersey facility and new sites in Houston, Chicago and Los Angeles, and has committed to significant equipment and construction spending and a DOE thorium‑228 supply agreement as it prepares for later‑stage trials and potential commercialization.
Perspective Therapeutics, Inc. reported second quarter 2026 results and provided a broad pipeline and manufacturing update. The company is advancing bamzireotide navoxetan (VMT-α-NET) toward a planned Phase 3 study in SSTR2-positive neuroendocrine tumors, targeting clinical site activation around year-end 2026, subject to regulatory feedback and protocol finalization. VMT01 in MC1R-positive melanoma and PSV359 in FAP-α-positive solid tumors continue in Phase 1/2a development, while PSV594 remains in pre-IND work. An updated VMT-α-NET data set will be presented at ESMO on October 23, 2026.
The company is expanding its 212Pb-based radiopharmaceutical manufacturing network, expecting its Chicago metro site to complete construction in early 2027 and its Los Angeles metro site in the second half of 2027, for four regional sites by year-end 2027. Cash, cash equivalents, and short-term investments totaled $237 million as of June 30, 2026, up from $145 million at December 31, 2025, and are expected to fund planned clinical milestones and operational investments into late 2027.
For the quarter ended June 30, 2026, research and development expenses were $21.5 million versus $16.6 million a year earlier, and general and administrative expenses were $7.8 million versus $7.7 million. Net loss was $26.8 million, or $0.22 per share, compared with a net loss of $21.5 million, or $0.29 per share, in the prior-year quarter. Total assets were $392.0 million and stockholders’ equity was $323.9 million as of June 30, 2026. The company also appointed Paul Lyne, Ph.D. as Chief Science Officer.